Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Working Capital to Net Assets Ratio

Latest as of June 2026: -46.8%

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd working capital to net assets ratio. Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a Working Capital to Net Assets ratio of -46.8% as of June 2026. Working capital of CN¥-46.34 Million (current assets of CN¥243.72 Million minus current liabilities of CN¥290.07 Million) is measured against net assets of CN¥98.93 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 600671 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

-46.8%
Working Capital / Net Assets

Working Capital

CN¥-46.34 Million
CNY

Current Assets

CN¥243.72 Million
CNY

Current Liabilities

CN¥290.07 Million
CNY

Working Capital to Net Assets Ratio of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2025)

Working capital to net assets ratio of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2025. This chart shows how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's Working Capital to Net Assets ratio has evolved across 32 annual periods from 1993 to 2025. As of June 2026, the ratio stands at -46.8%, reflecting working capital of CN¥-46.34 Million against net assets of CN¥98.93 Million CNY. See how many days can Hangzhou TianMuShan Pharmaceutical Enter fund operations to measure how many days the company can operate on defensive assets alone.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Working Capital to Net Assets Ratio by Year (1993–2025)

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd working capital to net assets ratio by year from 1993 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2025, covering 32 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Hangzhou TianMuShan Pharmaceutical Enter total assets.

Year WC/NA Ratio Working Capital (CNY) Net Assets Current Assets Current Liabilities Change (pp)
2025 -57.4% CN¥-53.95 Million CN¥93.99 Million CN¥228.48 Million CN¥282.42 Million ▲ +17.5 pp
2024 -74.9% CN¥-63.67 Million CN¥85.02 Million CN¥222.71 Million CN¥286.38 Million ▼ -5.4 pp
2023 -69.5% CN¥-38.88 Million CN¥55.95 Million CN¥181.50 Million CN¥220.38 Million ▲ +2097.8 pp
2022 -2167.3% CN¥-97.09 Million CN¥4.48 Million CN¥124.13 Million CN¥221.22 Million ▼ -2066.5 pp
2021 -100.8% CN¥-65.08 Million CN¥64.56 Million CN¥186.08 Million CN¥251.15 Million ▼ -69.8 pp
2020 -31.0% CN¥-28.96 Million CN¥93.33 Million CN¥222.92 Million CN¥251.89 Million ▼ -77.3 pp
2019 46.3% CN¥61.70 Million CN¥133.33 Million CN¥266.35 Million CN¥204.65 Million ▲ +64.0 pp
2018 -17.7% CN¥-14.48 Million CN¥81.62 Million CN¥262.23 Million CN¥276.70 Million ▲ +7.6 pp
2017 -25.4% CN¥-24.43 Million CN¥96.27 Million CN¥226.07 Million CN¥250.50 Million ▲ +105.2 pp
2016 -130.6% CN¥-86.44 Million CN¥66.18 Million CN¥115.32 Million CN¥201.76 Million ▼ -0.2 pp
2015 -130.4% CN¥-81.84 Million CN¥62.76 Million CN¥101.29 Million CN¥183.13 Million ▼ -88.5 pp
2014 -42.0% CN¥-35.76 Million CN¥85.25 Million CN¥127.30 Million CN¥163.06 Million ▼ -29.3 pp
2013 -12.6% CN¥-12.02 Million CN¥95.26 Million CN¥184.79 Million CN¥196.81 Million ▲ +30.3 pp
2012 -42.9% CN¥-39.84 Million CN¥92.76 Million CN¥159.61 Million CN¥199.45 Million ▼ -67.5 pp
2011 24.5% CN¥44.86 Million CN¥182.84 Million CN¥219.06 Million CN¥174.20 Million ▲ +16.5 pp
2010 8.0% CN¥12.33 Million CN¥154.14 Million CN¥177.19 Million CN¥164.86 Million ▼ -15.4 pp
2009 23.4% CN¥43.93 Million CN¥187.74 Million CN¥183.66 Million CN¥139.73 Million ▼ -24.3 pp
2008 47.7% CN¥114.53 Million CN¥240.30 Million CN¥242.51 Million CN¥127.98 Million ▼ -2.8 pp
2007 50.5% CN¥142.90 Million CN¥282.93 Million CN¥270.98 Million CN¥128.08 Million ▼ -0.1 pp
2006 50.6% CN¥119.55 Million CN¥236.44 Million CN¥234.78 Million CN¥115.24 Million ▼ -0.3 pp
2005 50.9% CN¥121.79 Million CN¥239.39 Million CN¥254.31 Million CN¥132.52 Million ▼ -2.8 pp
2004 53.7% CN¥135.54 Million CN¥252.36 Million CN¥240.23 Million CN¥104.69 Million ▲ +2.1 pp
2003 51.6% CN¥125.16 Million CN¥242.64 Million CN¥228.64 Million CN¥103.48 Million ▲ +5.6 pp
2002 46.0% CN¥116.41 Million CN¥253.20 Million CN¥236.74 Million CN¥120.32 Million ▼ -1.1 pp
2001 47.0% CN¥118.39 Million CN¥251.63 Million CN¥275.51 Million CN¥157.11 Million ▲ +1.0 pp
2000 46.1% CN¥115.79 Million CN¥251.29 Million CN¥270.38 Million CN¥154.60 Million ▼ -1.9 pp
1999 48.0% CN¥117.22 Million CN¥244.10 Million CN¥212.79 Million CN¥95.58 Million ▲ +3.3 pp
1998 44.8% CN¥105.51 Million CN¥235.71 Million CN¥192.53 Million CN¥87.02 Million ▼ -0.4 pp
1997 45.2% CN¥101.77 Million CN¥225.25 Million CN¥172.04 Million CN¥70.27 Million ▼ -4.0 pp
1996 49.2% CN¥99.08 Million CN¥201.52 Million CN¥154.93 Million CN¥55.85 Million ▲ +15.6 pp
1995 33.6% CN¥58.45 Million CN¥174.02 Million CN¥147.34 Million CN¥88.89 Million ▼ -19.8 pp
1993 53.4% CN¥46.20 Million CN¥86.48 Million CN¥68.88 Million CN¥22.68 Million —
pp = percentage points